IDEMIA
30.6.2020 08:02:13 CEST | Business Wire | Press release
The supervisory board of IDEMIA has appointed Pierre Barrial as the new President & CEO of the Group, replacing Yann Delabrière who resumes his previous role as Chairman of the Board. Matthew Cole, who has joined the Group, has taken on Pierre Barrial’s previous position as head of the Secure Enterprise Transactions (SET) division.
Over the last 18 months, IDEMIA has restored its growth and cash generation performance after the creation and successful integration of IDEMIA. Yann, who became President & CEO on October 18th 2018, will now be returning to his role as Chairman of the Board with effect from July 1st , 2020, where he will continue to contribute his strategic and governance insights to the company.
Pierre Barrial will succeed Yann as the Group’s President & CEO. He brings over 25 years’ experience with multinational and multicultural tech companies serving both the government and enterprise sectors. Pierre was in charge of SET, having previously managed IDEMIA’s Mobile Operators then Financial Institutions activities, both today part of the SET division. He has partnered with Yann since the beginning of the year as Deputy CEO. Pierre will become IDEMIA’s Group President & CEO starting July 1st , 2020.
Matthew Cole is appointed as head of the SET division, replacing Pierre Barrial. Matthew brings a wealth of experience in this space, having been President of Cubic Transportation Systems, the leading integrator of payment and information solutions and related services for intelligent travel applications in the transportation industry. He will be based in the US and will sit on the Group Executive Committee, as SET division’s CEO.
Yann Delabrière stated: “After a carefully prepared succession plan, we have chosen a world-class executive, Pierre Barrial, to manage the Group. IDEMIA has demonstrated remarkable resilience since the beginning of this year and our business fundamentals are strong and bode well for the future. On behalf of the Board, I wish Pierre all the very best in his new role.”
Pierre Barrial added: “I’m honored and excited to have been chosen as CEO of the Group. IDEMIA has an extremely committed team of 15,000 employees worldwide and together, we’ll continue to serve our clients regardless of the circumstances. I am also proud to head a company whose purpose, since its creation, is to make the world a safer place, whenever and wherever Identity & Security matter in an increasingly digital world. With recent events, this is more true than ever.”
Matthew Cole said: “I am thrilled and proud to join IDEMIA as CEO of the SET division. I plan to work hand in hand with my teams and Group senior management to bring the company’s strategy and growth targets to fruition.”
About Yann Delabrière
Yann Delabrière is a graduate of Ecole Normale Supérieure and Ecole Nationale d’Administration and has a postgraduate degree in mathematics. He began his career at the Committee of Public Accounts (Cour des Comptes) before working for the French External Trade Minister. He then became Chief Financial Officer for the French export credit agency, COFACE, followed by Printemps Group, before becoming Chief Financial Officer for PSA Peugeot Citroën in 1990 and, from 1998, was Chairman and Chief Executive Officer of Banque PSA Finance and sat on the PSA Peugeot Citroën Executive Committee. In 2007 Yann was appointed Chairman and Chief Executive Officer of Faurecia. From June 2017 to February 2018, he chaired the Zodiac Aerospace executive board. From 2004 to May 2018 he was a director of Cap Gemini, from 2012 to 2016 a director of Société Générale and since March 2017 has been a director of Alstom. He has chaired the IDEMIA executive board since October 2018 having previously chaired the IDEMIA supervisory board for a 10-month period.
About Pierre Barrial
Pierre Barrial graduated from Paris School of Business. He comes with over 25 years experience with multinational and multicultural firms and agencies from a broad array of industries including ICT and security, serving both the public and private sectors. After Pierre joined IDEMIA in 2013, he managed the Group’s Latin American operations followed by the Mobile Operators business, the Financial Institutions business and SET. Previously, Pierre worked in various jobs for Bull Group in South Africa, Italy, Poland and Brazil.
About Matthew Cole
Matthew Cole holds an MBA from Oxford Brookes University and is also Chartered Certified Accountant. In 2003 he joined Cubic Corporation, the world leader in smart and contactless payments for transportation. During his time at Cubic Matthew held several senior finance positions before successfully heading up the company’s Asia-Pacific operations followed by global Strategy and Business Development. In 2015, he became President of Cubic Transportation Systems. Before Cubic Corporation, Matthew held several positions with blue-chip multinational firms including Endemol, British Airways, Mitsui, First Choice and Schlumberger.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005779/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
